6274-29-9

Basic information

• Product Name: 2-amino-5-methoxy-benzenethiol
• Synonyms: 2-amino-5-methoxy-benzenethiol;5-Methoxy-3-phenylthiophen-2-aMine;Benzenethiol, 2-aMino-5-Methoxy-;5-Methoxy-2-aminobenzenethiol;5-Methoxy-2-aminothiophenol;NSC 36967;2-Mercapto-4-methoxyaniline
• CAS NO: 6274-29-9
• Molecular Formula: C₇H₉NOS
• Molecular Weight: 155.22
• Mol File: 6274-29-9.mol
• Article Data: 58

Chemical Properties

• Melting Point: 103-105 °C(Solv: ethanol (64-17-5))
• Boiling Point: 289.7°C at 760 mmHg
• Flash Point: 129°C
• Appearance: /
• Density: 1.209g/cm³
• Vapor Pressure: 0.00216mmHg at 25°C
• Refractive Index: 1.624
• Storage Temp.: Hygroscopic, Refrigerator, under inert atmosphere
• Solubility: DMSO (Slightly), Methanol (Slightly)
• PKA: 9.01±0.10(Predicted)
• Stability: Unstable in Solution, Unstable in Air
• CAS DataBase Reference: 2-amino-5-methoxy-benzenethiol(CAS DataBase Reference)
• NIST Chemistry Reference: 2-amino-5-methoxy-benzenethiol(6274-29-9)
• EPA Substance Registry System: 2-amino-5-methoxy-benzenethiol(6274-29-9)

Safety Data

• Hazardous Substances Data: 6274-29-9(Hazardous Substances Data)

Usage

Uses

2-Amino-5-methoxythiophenol is a chemical reagent used in the synthesis of antibacterial benzothiazepines.

InChI:InChI=1/C7H9NOS/c1-9-5-2-3-6(8)7(10)4-5/h2-4,10H,8H2,1H3

Upstream product

• 35576-56-8 6-methoxy-1,2,3-benzodithiazolium chloride 
• 54346-87-1 2-amino-5-methoxybenzothiazole 
• 104-94-9 4-methoxy-aniline 
• 1367199-65-2 BrH*C₈H₈N₂OS 
• 20265-97-8 p-anisidine hydrochloride 
• 1747-60-0 6-methoxybenzothiazol-2-ylamine 
• 7732-36-7 bis(2-amino-5-methoxyphenyl)disulfide 
• 2293-07-4 1-(4-methoxyphenyl)thiourea 

Downstream Products

• 2941-72-2 6-methoxy-2-methylbenzothiazole 
• 500797-83-1 thiobenzoic acid S-(2-benzoylamino-5-methoxy-phenyl ester) 
• 83516-41-0 4-Methoxy-2-(3-nitro-pyridin-2-ylsulfanyl)-phenylamine 
• 100601-17-0 threo-2-hydroxy-3-<(2-amino-5-methoxyphenyl)thio>-3-(4-methoxyphenyl)propionic acid methyl ester 
• 101078-75-5 2-<4-(bromomethyl)phenyl>-6-methoxybenzothiazole 
• 98120-09-3 2-(p-chlorobenzoyl)-7-methoxy-3-methyl-4H-1,4-benzothiazine 
• 124414-26-2 8-Methoxy-4-p-tolyl-2,3-dihydro-benzo[b][1,4]thiazepine-2-carboxylic acid 
• 123533-58-4 8-Methoxy-4-(4-methoxy-phenyl)-2,3-dihydro-benzo[b][1,4]thiazepine-2-carboxylic acid 
• 116626-01-8 4-(4-Chloro-phenyl)-8-methoxy-2-(4-methoxy-phenyl)-2,3-dihydro-benzo[b][1,4]thiazepine 
• 128462-38-4 (3,4-Dimethoxy-phenyl)-(7-methoxy-3-methyl-4H-benzo[1,4]thiazin-2-yl)-methanone 
• 137482-44-1 (2-Bromo-phenyl)-(7-methoxy-3-methyl-4H-benzo[1,4]thiazin-2-yl)-methanone 
• 121364-20-3 Biphenyl-4-yl-(7-methoxy-3-methyl-4H-benzo[1,4]thiazin-2-yl)-methanone 
• 19693-13-1 2-Nitro-6'-amino-3'-methoxy-4-acetyl-diphenylsulfid 

Relevant articles and documents

A polymerizable Aggregation Induced Emission (AIE)-active dye with remarkable pH fluorescence switching based on benzothiazole and its application in biological imaging

In recent years, Aggregation Induced Emission (AIE)-active fluorescent materials have been attracting considerable attention because they play an important role in clinical medicine, photoelectricity, environmental science, biological imaging, and sensors. In this contribution, a novel tetraphenylethylene (TPE) derivative of 2-(4-(1,2,2-triphenylvinyl)benzene) benzothiazole methacrylate (TPBMA) monomer was synthesized by a Suzuki coupling and an acylation reaction using TPE and benzothiazole as structural units, whose maximum emission wavelength respectively appeared at 506 nm in neutral medium and 579 nm in acidic medium with excellent pH sensitivity, and it could change repeatedly at 500 nm and 579 nm under HCl/NH3 fuming, indicating the reversible fluorescence conversion property. As compared with the TPB dye, the emission wavelength of TPBMA spectra has an obvious red-shift, which is consistent with the transition energy level difference (△E) of highest occupied molecular orbital (HOMO) and lowest unoccupied orbital (LUMO) situation by quantum chemistry calculation. Subsequently, the copolymers PEG-TB were successfully prepared by RAFT polymerization of TPBMA and poly (ethylene glycol) monomethacrylate (PEGMA), and their molecular weight (Mw) was about 2.12 × 104 with a narrow polydispersity index (PDI). From the 1H NMR analysis, the actual fraction of TPBMA in the PEG-TB copolymers increased to 22.6% from 17.4% when the feed ratio of TBMTA changed to 25.0% from 20.0%. The obtained PEG-TB could self-assemble into fluorescent organic nanoparticles (FONs) with 100–150 nm diameter in aqueous solution, and their fluorescence intensity increased gradually with the increase of water fraction in the THF solution, indicating the obvious AIE behavior. Moreover, the as-prepared PEG-TB FONs exhibited the prospective potential in the field of biological imaging due to their low cytotoxicity, excellent biocompatibility and easy cells absorption.

Metal-chelating benzothiazole multifunctional compounds for the modulation and 64Cu PET imaging of Aβ aggregation

While Alzheimer's Disease (AD) is the most common neurodegenerative disease, there is still a dearth of efficient therapeutic and diagnostic agents for this disorder. Reported herein are a series of new multifunctional compounds (MFCs) with appreciable affinity for amyloid aggregates that can be potentially used for both the modulation of Aβ aggregation and its toxicity, as well as positron emission tomography (PET) imaging of Aβ aggregates. Firstly, among the six compounds tested HYR-16 is shown to be capable to reroute the toxic Cu-mediated Aβ oligomerization into the formation of less toxic amyloid fibrils. In addition, HYR-16 can also alleviate the formation of reactive oxygen species (ROS) caused by Cu2+ ions through Fenton-like reactions. Secondly, these MFCs can be easily converted to PET imaging agents by pre-chelation with the 64Cu radioisotope, and the Cu complexes of HYR-4 and HYR-17 exhibit good fluorescent staining and radiolabeling of amyloid plaques both in vitro and ex vivo. Importantly, the 64Cu-labeled HYR-17 is shown to have a significant brain uptake of up to 0.99 ± 0.04 percentID per g. Overall, by evaluating the various properties of these MFCs valuable structure-activity relationships were obtained that should aid the design of improved therapeutic and diagnostic agents for AD. This journal is

A Novel Difluoroacetic Acid Derivatives Compound, and Composition Comprising the Same

The present invention relates to a novel difluoroacetic acid derivative compound and a composition for various uses containing the same, wherein the difluoroacetic acid derivative compound can not only act as an agonist activating one among PPARandalpha;, andbeta; or andgamma;, but also can exhibit double efficacy or triple efficacy. Therefore, the difluoroacetic acid derivative compound can more effectively prevent, alleviate or treat metabolic diseases in which PPARs involves, and further exhibits whitening and wrinkle alleviation activity, and anti-inflammatory and antioxidant effects, thereby being able to be usefully utilized as various compositions.COPYRIGHT KIPO 2020